Insider Transactions in Q3 2021 at Opiant Pharmaceuticals, Inc. (OPNT)
Insider Transaction List (Q3 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 22
2021
|
Thomas T. Thomas Director |
SELL
Open market or private sale
|
Direct |
735
-6.62%
|
$18,375
$25.02 P/Share
|
|
Sep 22
2021
|
Thomas T. Thomas Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,834
+14.17%
|
$18,340
$10.0 P/Share
|
|
Sep 21
2021
|
Thomas T. Thomas Director |
SELL
Open market or private sale
|
Direct |
831
-4.13%
|
$19,944
$24.1 P/Share
|
|
Sep 21
2021
|
Thomas T. Thomas Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+16.52%
|
$20,000
$10.0 P/Share
|
|
Sep 16
2021
|
Roger Crystal Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
100
+1.92%
|
$2,300
$23.44 P/Share
|
|
Sep 14
2021
|
Thomas T. Thomas Director |
SELL
Open market or private sale
|
Direct |
1,571
-6.18%
|
$29,849
$19.24 P/Share
|
|
Sep 14
2021
|
Thomas T. Thomas Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,025
+10.12%
|
$30,250
$10.0 P/Share
|
|
Sep 14
2021
|
David D O'Toole Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
200
+0.41%
|
$3,800
$19.09 P/Share
|
|
Sep 14
2021
|
Brian Gorman |
BUY
Open market or private purchase
|
Direct |
1,312
+2.87%
|
$24,928
$19.01 P/Share
|
|
Sep 13
2021
|
Craig A Collard Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,206
+3.43%
|
$21,708
$18.01 P/Share
|
|
Sep 13
2021
|
Craig A Collard Director |
BUY
Open market or private purchase
|
Direct |
2,500
+13.46%
|
$45,000
$18.13 P/Share
|
|
Sep 10
2021
|
Craig A Collard Director |
BUY
Open market or private purchase
|
Direct |
9,577
+41.36%
|
$172,386
$18.18 P/Share
|
|
Sep 07
2021
|
Thomas T. Thomas Director |
SELL
Open market or private sale
|
Direct |
822
-11.0%
|
$14,796
$18.0 P/Share
|
|
Sep 07
2021
|
Thomas T. Thomas Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,475
+16.48%
|
$14,750
$10.0 P/Share
|
|
Aug 31
2021
|
Matthew R. Ruth Chief Commercial Officer |
BUY
Open market or private purchase
|
Direct |
2,000
+10.53%
|
$34,000
$17.34 P/Share
|
|
Aug 25
2021
|
Michael Sinclair Director |
SELL
Open market or private sale
|
Direct |
50,269
-25.87%
|
$703,766
$14.69 P/Share
|
|
Aug 25
2021
|
Michael Sinclair Director |
BUY
Exercise of conversion of derivative security
|
Direct |
50,269
+20.55%
|
$251,345
$5.0 P/Share
|
|
Aug 24
2021
|
Michael Sinclair Director |
SELL
Open market or private sale
|
Direct |
34,607
-19.37%
|
$519,105
$15.71 P/Share
|
|
Aug 24
2021
|
Michael Sinclair Director |
BUY
Exercise of conversion of derivative security
|
Direct |
34,607
+16.23%
|
$173,035
$5.0 P/Share
|
|
Aug 23
2021
|
Michael Sinclair Director |
SELL
Open market or private sale
|
Direct |
65,124
-31.13%
|
$1,041,984
$16.5 P/Share
|
|
Aug 23
2021
|
Michael Sinclair Director |
BUY
Exercise of conversion of derivative security
|
Direct |
65,124
+23.74%
|
$325,620
$5.0 P/Share
|
|
Aug 19
2021
|
Thomas T. Thomas Director |
SELL
Open market or private sale
|
Direct |
1,000
-7.41%
|
$16,000
$16.23 P/Share
|
|
Aug 16
2021
|
David D O'Toole Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
600
+2.46%
|
$9,000
$15.38 P/Share
|
|
Jul 19
2021
|
Matthew R. Ruth Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+50.0%
|
-
|